Hims & Hers Health (HIMS) Scheduled to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is scheduled to announce its earnings results after the market closes on Monday, November 4th. Analysts expect Hims & Hers Health to post earnings of $0.06 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. The business’s quarterly revenue was up 51.8% compared to the same quarter last year. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Trading Up 8.2 %

Shares of NYSE:HIMS opened at $20.37 on Friday. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of 254.66 and a beta of 1.06. The stock’s 50-day moving average price is $18.01 and its two-hundred day moving average price is $18.06. Hims & Hers Health has a 12-month low of $5.97 and a 12-month high of $25.74.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now owns 145,763 shares in the company, valued at $2,960,446.53. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 2,334 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total value of $40,378.20. Following the transaction, the insider now directly owns 164,475 shares of the company’s stock, valued at $2,845,417.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 269,739 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the sale, the chief financial officer now directly owns 145,763 shares of the company’s stock, valued at $2,960,446.53. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 858,665 shares of company stock worth $15,148,890 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Piper Sandler reissued a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Needham & Company LLC assumed coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Bank of America lifted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Truist Financial upped their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.